Compound Detail
CHEMBL1501
FLUOCINONIDE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
Basic Information
| ChEMBL ID | CHEMBL1501 |
| Name | FLUOCINONIDE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | WJOHZNCJWYWUJD-IUGZLZTKSA-N |
| Therapeutic | ✓ Yes |
2
Targets
4
Activities
2
Assay Types
0
PK Parameters
20
Publications
10
Known Names
5
Indications
1
Mechanisms
Molecular Properties
494.5
MW (Da)
2.94
ALogP
7
HBA
1
HBD
99.1
PSA (Ų)
0.60
QED
0
Ro5 Violations
3
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1971 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Glucocorticoid receptor agonist | AGONIST | Glucocorticoid receptor | ✓ | ✓ |
Indications
Hemorrhoids Skin Diseases Breast Neoplasms Dermatitis, Atopic Psoriasis
ATC Classification
C05AA11
fluocinonide
Level 1: CARDIOVASCULAR SYSTEM
Level 2: VASOPROTECTIVES
D07AC08
fluocinonide
Level 1: DERMATOLOGICALS
Level 2: CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
Drug Warnings
Black Box Warning
General Warning
Activity Summary
IC50 2 meas. best 8.28
Ki 2 meas. best 8.62
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Glucocorticoid receptor CHEMBL2034 | Ki | 8.62 | 8.62 | 2.4 | 1 |
| Progesterone receptor CHEMBL1909044 | Ki | 8.54 | 8.54 | 2.9 | 1 |
| Glucocorticoid receptor CHEMBL2034 | IC50 | 8.28 | 8.28 | 5.3 | 1 |
| Progesterone receptor CHEMBL1909044 | IC50 | 7.66 | 7.66 | 22.0 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Glucocorticoid receptor | Ki | = | 2.392 | nM | 8.62 | DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) | - |
| Progesterone receptor | Ki | = | 2.904 | nM | 8.54 | DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) | - |
| Glucocorticoid receptor | IC50 | = | 5.263 | nM | 8.28 | DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) | - |
| Progesterone receptor | IC50 | = | 22.0 | nM | 7.66 | DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) | - |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 6 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 4 |
| - | 10.6019/CHEMBL4495564 | Replicase polyprotein 1ab | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Thromboxane A2 receptor | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Prostaglandin G/H synthase 1 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 2 |
| - | 10.21203/rs.3.rs-23951/v1 | SARS-CoV-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M1 | 2 |
| - | 10.1101/2020.04.21.054387 | SARS-CoV-2 | 1 |
| - | 10.6019/CHEMBL4513141 | Candida albicans | 1 |
| - | 10.6019/CHEMBL4513141 | Cryptococcus neoformans | 1 |
| - | 10.6019/CHEMBL4513141 | Escherichia coli | 1 |
| - | 10.6019/CHEMBL4513141 | Klebsiella pneumoniae | 1 |
| 23571415 | 10.1124/mol.112.084152 | Solute carrier organic anion transporter family member 1B3 | 1 |
| - | 10.6019/CHEMBL4513141 | Acinetobacter baumannii | 1 |
| 23571415 | 10.1124/mol.112.084152 | Solute carrier organic anion transporter family member 1B1 | 1 |
| 38318365 | 10.1016/j.isci.2024.108907 | Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 | 1 |
| 3783574 | 10.1021/jm00161a001 | Homo sapiens | 1 |
Data from ChEMBL 36 via Core Engine